Chimerix (CMRX) Downgraded by Zacks Investment Research

Chimerix (NASDAQ:CMRX) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued to investors on Monday.

According to Zacks, “Chimerix, Inc. engages in the discovery, development and commercialization of oral antiviral therapeutics for various medical needs. The Company is developing various product candidates for the treatment of dsDNA viruses, HIV, hepatitis C, influenza and smallpox which are under different phases of clinical development. It is also screening our proprietary Chimerix Chemical Library for compounds with activity against dengue virus, malaria and tuberculosis. Chimerix, Inc. is headquartered in Durham, North Carolina. “

Separately, ValuEngine downgraded Chimerix from a “sell” rating to a “strong sell” rating in a report on Thursday, November 9th.

Chimerix (NASDAQ CMRX) traded up $0.02 during midday trading on Monday, reaching $4.95. The company had a trading volume of 136,191 shares, compared to its average volume of 235,014. The company has a market cap of $232.34, a price-to-earnings ratio of -3.46 and a beta of 1.46. Chimerix has a 1-year low of $4.17 and a 1-year high of $6.64.

Chimerix (NASDAQ:CMRX) last released its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.37) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.43) by $0.06. The business had revenue of $0.90 million for the quarter, compared to analyst estimates of $0.81 million. Chimerix had a negative return on equity of 26.00% and a negative net margin of 1,440.67%. equities analysts predict that Chimerix will post -1.6 EPS for the current year.

In other news, insider Linda M. Richardson sold 19,833 shares of the stock in a transaction on Friday, December 1st. The stock was sold at an average price of $4.47, for a total value of $88,653.51. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 4.40% of the company’s stock.

Several hedge funds have recently bought and sold shares of the company. Acadian Asset Management LLC acquired a new position in shares of Chimerix in the 4th quarter valued at $280,000. Schwab Charles Investment Management Inc. lifted its stake in shares of Chimerix by 5.4% in the 4th quarter. Schwab Charles Investment Management Inc. now owns 211,655 shares of the biopharmaceutical company’s stock valued at $980,000 after purchasing an additional 10,764 shares during the period. Dimensional Fund Advisors LP lifted its stake in shares of Chimerix by 19.3% in the 3rd quarter. Dimensional Fund Advisors LP now owns 1,728,095 shares of the biopharmaceutical company’s stock valued at $9,072,000 after purchasing an additional 279,845 shares during the period. Citadel Advisors LLC lifted its stake in shares of Chimerix by 131.8% in the 3rd quarter. Citadel Advisors LLC now owns 165,490 shares of the biopharmaceutical company’s stock valued at $869,000 after purchasing an additional 94,108 shares during the period. Finally, Granite Investment Partners LLC lifted its stake in shares of Chimerix by 36.6% in the 3rd quarter. Granite Investment Partners LLC now owns 108,947 shares of the biopharmaceutical company’s stock valued at $572,000 after purchasing an additional 29,194 shares during the period. 70.35% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: “Chimerix (CMRX) Downgraded by Zacks Investment Research” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The original version of this piece can be accessed at https://www.americanbankingnews.com/2018/01/22/chimerix-cmrx-downgraded-by-zacks-investment-research.html.

Chimerix Company Profile

Chimerix, Inc is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses.

Get a free copy of the Zacks research report on Chimerix (CMRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply